These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21812901)

  • 1. The impact of hypertriglyceridemia on prostate cancer development in patients aged ≥60 years.
    Hayashi N; Matsushima M; Yamamoto T; Sasaki H; Takahashi H; Egawa S
    BJU Int; 2012 Feb; 109(4):515-9. PubMed ID: 21812901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The uncertain relationship between obesity and prostate cancer: an Italian biopsy cohort analysis.
    De Nunzio C; Freedland SJ; Miano L; Finazzi Agrò E; Bañez L; Tubaro A
    Eur J Surg Oncol; 2011 Dec; 37(12):1025-9. PubMed ID: 21963050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer.
    Ochiai A; Fritsche HA; Babaian RJ
    Urology; 2005 Oct; 66(4):819-23. PubMed ID: 16230145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical impact of body mass index on prostate biopsy in patients with intermediate PSA levels].
    Sekita N; Suzuki H; Kamijima S; Chini K; Fujimura M; Mikami K
    Hinyokika Kiyo; 2008 Jul; 54(7):479-83. PubMed ID: 18697492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
    Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of common medications on serum total prostate-specific antigen levels and risk group assignment in patients with prostate cancer.
    Nieder C; Norum J; Geinitz H
    Anticancer Res; 2011 May; 31(5):1735-9. PubMed ID: 21617232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of statin medications on prostate-specific antigen levels.
    Hamilton RJ; Goldberg KC; Platz EA; Freedland SJ
    J Natl Cancer Inst; 2008 Nov; 100(21):1511-8. PubMed ID: 18957682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between prostate-specific antigen bounce body fat distribution and body mass index in permanent seed brachytherapy for prostate cancer.
    Delouya G; Taussky D; Ji CR; Sylvestre MP; Donath D
    Brachytherapy; 2012; 11(3):214-8. PubMed ID: 21700507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
    Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
    Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
    Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
    J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
    Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body mass index as a predictor of prostate cancer: development versus detection on biopsy.
    Freedland SJ; Terris MK; Platz EA; Presti JC
    Urology; 2005 Jul; 66(1):108-13. PubMed ID: 15992911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
    Makarov DV; Sanderson H; Partin AW; Epstein JI
    J Urol; 2002 Jun; 167(6):2440-2. PubMed ID: 11992053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertriglyceridemia as a possible risk factor for prostate cancer.
    Wuermli L; Joerger M; Henz S; Schmid HP; Riesen WF; Thomas G; Krek W; Cerny T; Gillessen S
    Prostate Cancer Prostatic Dis; 2005; 8(4):316-20. PubMed ID: 16158078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer.
    Krane LS; Menon M; Kaul SA; Siddiqui SA; Wambi C; Peabody JO; Agarwal PK
    Urol Oncol; 2011; 29(4):372-7. PubMed ID: 19576796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
    Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.